Iraglim-M 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The synergistic action of these agents effectively controls hyperglycemia in patients inadequately managed by diet and exercise alone. Iraglim-M 2 Tablet PR is typically prescribed when monotherapy with either agent is insufficient or when combination therapy is preferred for better glycemic control. It is important to administer the medication with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea and diarrhea. Regular monitoring of blood glucose, renal function, and hepatic parameters is recommended during therapy. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. Iraglim-M 2 Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and weight control to optimize therapeutic outcomes and reduce the risk of diabetes-related complications.